Literature DB >> 8055460

Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.

K M Greven1, D W Williams, J W Keyes, W F McGuirt, N E Watson, M E Randall, M Raben, K R Geisinger, J O Cappellari.   

Abstract

BACKGROUND: Positron emission tomography (PET) with labeled fluorodeoxyglucose (FDG) demonstrates increased tracer uptake in many neoplasms. This study was undertaken to define the patterns of FDG uptake in head and neck neoplasms before and after high dose irradiation.
METHODS: Twenty-five patients were evaluated prospectively with PET and standard clinical and radiographic techniques before and after irradiation.
RESULTS: Twenty-seven primary sites were confirmed pathologically in 23 patients and included the nasopharynx (four lesions), oropharynx (14 lesions), larynx (five lesions), oral cavity (two lesions), and paranasal sinuses (two lesions). Two patients had unknown primary sites. Twenty-four of 27 primary sites correlated with areas of increased tracer uptake on PET scans. Five patients had increased uptake in cervical lymph nodes that were uninvolved by radiographic or clinical criteria. Positron emission tomography seemed to be able to differentiate tumor activity from fluid-filled sinuses in two patients with paranasal sinus tumors. In two patients with unknown primary sites, increased uptake in the base of tongue after PET suggested occult primary sites. Positron emission tomography scans obtained 1 month after high dose irradiation (RT) indicated decreased levels of FDG uptake in all patients' tumors. However, these scans did not accurately reflect the status of disease in these patients. Scans obtained 4 months after RT were believed to assess more accurately the presence of malignancy.
CONCLUSIONS: Positron emission tomography is a new modality that may be useful in defining tumor activity in clinically negative areas. Appropriately timed posttreatment PET may be useful in predicting outcome after definitive RT and in distinguishing viable tumors from normal tissue changes after RT in patients with head and neck carcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055460     DOI: 10.1002/1097-0142(19940815)74:4<1355::aid-cncr2820740428>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement.

Authors:  Jolijn Brouwer; Evelien J Bodar; Remco De Bree; Johannes A Langendijk; Jonas A Castelijns; Otto S Hoekstra; C René Leemans
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-11-19       Impact factor: 2.503

Review 2.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  Comparison of thallium-201 SPET and CT/MRI in the detection of residual/recurrent squamous cell carcinoma of the oral cavity.

Authors:  Jong-Kang Lee; Yeu-Sheng Tyan; Wen-Sheng Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 4.  The role of FDG PET-CT in the therapeutic evaluation for HNSCC patients.

Authors:  Joji Kawabe; Shigeaki Higashiyama; Atsushi Yoshida; Kohei Kotani; Susumu Shiomi
Journal:  Jpn J Radiol       Date:  2012-04-05       Impact factor: 2.374

5.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 7.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

Review 8.  Efficacy of neck dissection in the management of isolated nodal recurrence after head and neck cancer treatment.

Authors:  Jimmy Yu-wai Chan
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

9.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.